CRO Concept Life Sciences opened its expanded integrated drug discovery facilities at its Chapel-en-le-Frith site in the U.K. This expansion brings chemistry, ADMET, and screening biology capabilities together under one roof with 130 scientists now on site, according to a company spokesperson, who adds that this represents a key milestone in Concept’s mission to accelerate the development of life-changing therapies, enhancing its ability to provide streamlined integrated drug discovery services that unlock progress in early-stage innovation through efficient workflows and troubleshooting.
The expanded facilities, which include custom-fit drug discovery solutions across a range of modalities and therapy areas, are also expected to provide high-value life-sciences job opportunities in the Manchester and Sheffield region. The company’s headquarters is now one of the U.K.’s largest drug discovery research sites, notes Jonathan Critchley, chief financial officer at Concept Life Sciences.
“This expansion of our facilities strengthens our ability to turn breakthrough science into viable, fundable, and clinically impact therapies through our integrated drug discovery capabilities,” he explains. As a client-centric CRO with scientific and regulatory expertise we don’t just deliver on the science for our clients, we provide a tailored solution-oriented approach to enable early-stage research companies to overcome unique drug discovery challenges.”
